Beiersdorf’s Q3 26 group sales reached €2.362 billion, up 0.4% reported but down 1.3% organically. For the first nine months, sales were €7.314 billion, down 3.0% reported and 2.8% organically. The Consumer business generated €1.940 billion, down 0.7% organically; tesa sales fell 4.3% to €422 million. The Q3 results release does not report quarterly profit figures.
Consumer generated 82% of group sales. Its organic sales decline eased to 0.7% in Q3 from 4.0% in H1. NIVEA and Labello fell 4.9% organically. Temporary retailer disputes and destocking weighed on sell-in, although net sales dynamics improved versus Q2 and global sell-out continued to grow.
Derma grew 10.6% organically, with growth across regions and categories. Beiersdorf cited Aquaphor’s expansion into U.S. body care and the launch of Eucerin DERMOPURE CLINICAL PROBIOM8. Health Care grew 5.7%, supported by wound-care innovation. La Prairie accelerated to 8.5%, with China the key growth driver.
Regional trends also diverged: Consumer sales fell 5.3% organically in Europe, while the Americas grew 3.6% and Africa/Asia/Australia grew 2.3%. tesa declined 4.3% as semiconductor shortages affected Electronics; excluding Electronics, its broader Industry portfolio developed positively.
Beiersdorf confirmed full-year Group guidance of a low-single-digit organic sales decline and EBIT margin excluding special factors of at least 11.8%. Consumer guidance is a low-single-digit organic sales decline and margin of at least 11.0%. tesa expects flat to slightly growing organic sales and a margin slightly below last year; chip shortages remain a downside risk. Source: Beiersdorf Third-quarter 2026 results release and Q3 results speech.
